Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) shares purchased by Envestnet Asset Management Inc.

0

Envestnet Asset Management Inc. increased its equity stake in Fresenius Medical Care AG & Co. KGaA (New York Stock Exchange: FMSGet a rating) by 94.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund held 251,391 shares of the company after acquiring an additional 122,169 shares during the period. Envestnet Asset Management Inc.’s holdings in Fresenius Medical Care AG & Co. KGaA were worth $8,467,000 at the end of the most recent period.

A number of other hedge funds and other institutional investors have also recently increased or reduced their stakes in FMS. Pzena Investment Management LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 47.6% in the fourth quarter. Pzena Investment Management LLC now owns 9,459,446 shares of the company valued at $307,054,000 after purchasing an additional 3,051,672 shares in the last quarter. First Trust Advisors LP raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 15.1% in the fourth quarter. First Trust Advisors LP now owns 1,925,326 shares of the company valued at $62,496,000 after purchasing an additional 252,768 shares in the last quarter. Cambiar Investors LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 18.3% in the first quarter. Cambiar Investors LLC now owns 1,363,874 shares of the company valued at $45,935,000 after purchasing an additional 210,819 shares in the last quarter. Invesco Ltd. raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 54.0% in the fourth quarter. Invesco Ltd. now owns 376,173 shares of the company valued at $12,211,000 after purchasing an additional 131,870 shares in the last quarter. Finally, Timber Creek Capital Management LLC increased its position in shares of Fresenius Medical Care AG & Co. KGaA by 5.1% in the first quarter. Timber Creek Capital Management LLC now owns 198,743 shares of the company valued at $6,693,000 after purchasing an additional 9,695 shares in the last quarter. Institutional investors and hedge funds hold 4.73% of the company’s shares.

Pricing performance of Fresenius Medical Care AG & Co. KGaA

FMS opened at $18.66 on Tuesday. The company has a quick ratio of 0.85, a current ratio of 1.18 and a debt ratio of 0.47. Fresenius Medical Care AG & Co. KGaA has a 52 week minimum of $18.16 and a 52 week maximum of $40.85. The company has a 50-day moving average of $24.13 and a two-hundred-day moving average of $29.46. The company has a market capitalization of $10.94 billion, a P/E ratio of 11.89, a P/E/G ratio of 0.92 and a beta of 1.03.

A Wall Street analyst gives his opinion

A number of research companies have weighed in on FMS recently. StockNews.com downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong buy” rating to a “buy” rating in a Friday, July 15 research report. JPMorgan Chase & Co. lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from €51.00 ($52.04) to €23.00 ($23.47) in a research report Monday, August 1. UBS Group downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a Friday, July 29 research report. DZ Bank downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a Friday, July 29 research report. Finally, Truist Financial lowered its price target on shares of Fresenius Medical Care AG & Co. KGaA from $34.00 to $27.00 and set a “hold” rating for the company in a research report from the Wednesday, June 22. One financial analyst gave the stock a sell rating, seven gave the company a hold rating and four gave the company a buy rating. Based on MarketBeat data, Fresenius Medical Care AG & Co. KGaA currently has an average rating of “Hold” and a consensus price target of $49.01.

Fresenius Medical Care AG & Co. KGaA Profile

(Get a rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America and abroad. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; equipment, training and patient support services including clinical monitoring, assisting with follow-up and arranging delivery of supplies to the patient’s home; and contracted dialysis services with hospitals in the United States for hospitalized patients with end-stage renal disease (ESRD) and for patients with acute renal failure.

Further reading

Institutional ownership by quarter for Fresenius Medical Care AG & Co. KGaA (NYSE: FMS)



Get news and reviews for Fresenius Medical Care AG & Co. KGaA Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com’s free daily email newsletter .

Share.

Comments are closed.